Targacept Inc. - Articles and news items


Remaining TC-5214 Phase III efficacy studies do not meet endpoint, regulatory filing will not be pursued

Industry news, News / 20 March 2012 / AstraZeneca

Top-line results from the remaining Phase III studies – announced…


AstraZeneca and Targacept initiate phase IIB clinical trial of TC-5214 as a switch monotherapy treatment for major depressive disorder

Industry news, News / 7 February 2011 / AstraZeneca

This study is in addition to the companies’ Phase III RENAISSANCE programme for TC-5214…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...